Depakene and Visual disturbance - a phase IV clinical study of FDA data

Summary:

Visual disturbance is reported as a side effect among people who take Depakene (valproic acid), especially for people who are male, 60+ old, have been taking the drug for < 1 month also take Aranesp, and have Anaemia of malignant disease.

The phase IV clinical study analyzes which people have Visual disturbance when taking Depakene. It is created by eHealthMe based on reports of 14,611 people who have side effects when taking Depakene from the FDA, and is updated regularly.

What is Depakene?

Depakene has active ingredients of valproic acid. It is often used in epilepsy. eHealthMe is studying from 14,776 Depakene users. Check the latest studies of Depakene.

What is Visual disturbance?

Visual disturbance is found to be associated with 678 drugs and 976 conditions by eHealthMe. Check the latest studies of Visual disturbance.

On Jul, 05, 2026

14,611 people reported to have side effects when taking Depakene.
Among them, 18 people (0.12%) have Visual disturbance.

Could Depakene cause Visual disturbance?

Among these 18 people:

How long have people been on Depakene when they have Visual disturbance? *

What is the gender of people who have Visual disturbance when taking Depakene? *

female: 50 %
male: 50 %

What is the age of people who have Visual disturbance when taking Depakene? *

What are other drugs people take besides Depakene? *

What are other side effects people have besides Visual disturbance? *

Hypotonia (low muscle tone): 7 people, 38.89%
Hypoaesthesia (reduced sense of touch or sensation): 5 people, 27.78%
Memory Loss: 4 people, 22.22%
Scar: 2 people, 11.11%
Difficulty In Walking: 2 people, 11.11%
Diplopia (double vision): 2 people, 11.11%
Corneal Opacity (scarring or clouding of the cornea): 2 people, 11.11%
Dizziness: 2 people, 11.11%
Blood Lactate Dehydrogenase Increased: 2 people, 11.11%
Nasopharyngitis (inflammation of the nasopharynx): 2 people, 11.11%

What are the existing conditions these people have? *

Anaemia Of Malignant Disease: 4 people, 22.22%
Hypothyroidism (abnormally low activity of the thyroid gland, resulting in retardation of growth and mental development): 1 person, 5.56%
Convulsion (muscles contract and relax rapidly and repeatedly, resulting in an uncontrolled shaking of the body): 1 person, 5.56%
Cerebral Palsy: 1 person, 5.56%

* Approximation only. Some reports may have incomplete information.

Do you take Depakene and have Visual disturbance?

- Check whether Visual disturbance is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Depakene:

Depakene (14,776 reports)

Browse all side effects of Depakene:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Visual disturbance:

Visual disturbance (678 drugs)

Browse all the conditions that are associated with Visual disturbance:

Visual disturbance (976 conditions)

Related publications that referenced our studies

Gupta E, Kunjal R, Cury JD, "Severe hyponatremia due to valproic acid toxicity", Journal of clinical medicine research, 2015 Jan .
Hwabejire JO, Lu J, Liu B, Li Y, Halaweish I, Alam HB, "Valproic acid for the treatment of hemorrhagic shock: a dose-optimization study", journal of surgical research, 2014 Jan .
Gupta E, Kunjal R, Cury JD, "Severe hyponatremia due to valproic acid toxicity", Journal of clinical medicine research, 2015 Jan .
Hwabejire JO, Lu J, Liu B, Li Y, Halaweish I, Alam HB, "Valproic acid for the treatment of hemorrhagic shock: a dose-optimization study", journal of surgical research, 2014 Jan .

How the study uses the data?

The study uses data from the FDA. It is based on valproic acid (the active ingredients of Depakene) and Depakene (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.